Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 8/20 | 0.41 |
| ▸ | F10 | P00742 | 5/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997130 | 0.89 | KLKB1 (0.53) | KLKB1F10F2ARSCN9A | |
| SCHEMBL7478866 | 0.82 | ALOX5 (0.41) | KLKB1F10F2ARSCN9A | |
| SCHEMBL2000258 | 0.82 | F10 (0.38) | KLKB1F10F2ARSCN9A | |
| SCHEMBL7231373 | 0.80 | KLKB1 (0.51) | KLKB1 | |
| SCHEMBL7534729 | 0.79 | F10 (0.51) | KLKB1F10F2 | |
| SCHEMBL3831413 | 0.79 | TRPV1 (0.45) | ARPTGS2TRPV1 | |
| SCHEMBL3833223 | 0.79 | STIM1 (0.46) | ARSCN9APTGS1PTGS2ORAI1 | |
| SCHEMBL3830325 | 0.78 | TRPV1 (0.41) | ARPTGS2TRPV1 | |
| SCHEMBL28386908 | 0.77 | KLKB1 (0.44) | KLKB1F10F2ARSCN9A | |
| SCHEMBL23428978 | 0.76 | KLKB1 (0.52) | KLKB1F10F2ARPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603562-A4 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7122557-B2 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1603562-A2 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040209863-A1 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
| WO-2004083174-A2 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209863-A1 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | TFPI, SPINT2, TMPRSS4 | KLKB1 236/4885F10 37/4885F2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.